TVTX (Travere Corp) שולי רווח גולמי

TVTX (Travere Therapeutics Inc) - סמל מסחרי של החברה

Travere Therapeutics (TVTX) focuses on orphan kidney diseases, fully outsourcing product manufacturing and logistics to third-party contractors. This gross margin chart demonstrates cost management efficiency, with the current value standing at 90.40. The flawless delivery of specialized medications is critical for patients. Simultaneously, rapid sales growth of the core drug has stabilized liquidity and significantly limited the company's operating losses.

TVTX: שולי רווח גולמי Retrophin 04.07.2022 - 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Travere Therapeutics Inc (TVTX)

- סטטיסטיקת מזומנים ותזרימי מזומנים:
ניתוח מסכם של החברה:Retrophin (TVTX)
מוצרים מיוצרים של Travere Therapeutics, Inc.

Travere Therapeutics (TVTX) maintains premium pricing due to its strong scientific reputation in the treatment of rare kidney pathologies, which is reflected in the value of 90.40. By analyzing the gross profit margin, an investor can see the portion of revenue remaining after direct production costs, where steady growth of this indicator confirms operational efficiency and minimizes the risk of capital impairment.